The available prognostic parameters (lymph node status, tumor size, grade of malignancy, expression of steroid receptors and human epidermal growth factor receptor type 2 (HER2)) do not define the prognosis of individual patient after anthracycline treatment precisely. This evidence concerns the gene ERBB2 and neoplasm.